Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Indian Science
  4. Volume 2, Issue 1
  5. Article
Volume 2, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Diabetes Mellitus (DM) is a compounded, persistent illness symbolized by an increased range of glucose levels in the blood caused by cellular resistance to insulin action, insufficient insulin production by pancreatic -cells, or both. Type 1 Diabetes Mellitus (T1DM), the extremely widespread form of DM, is recorded for almost 85-90% of worldwide cases. T2DM is mostly common in middle-aged and older people, and its causes are multifaceted. The use of efficient and profitable solutions for DM screening is critical to ensure pre-identification and minimising patients' risk of acquiring the life-compromising illness. Identification of innovative biomarkers with test methods of DM is therefore critical in order to establish vigorous, non-invasive, pain-free, highly sensitive, and precise procedures for screening. The purpose of this review article is to mention and review all the necessary biomarkers that play a vital role in disease diagnosis and to highlight the present-day findings of the latest clinically validated and traditional biomarkers and procedures for determining them, which provide cost-efficient options for T2DM screening with early detection. It is concluded that various biomarkers, both conventional and innovative, go hand in hand to diagnose the DM of any type.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X257270231127062630
2023-12-20
2024-12-28

  • From This Site

    /content/journals/cis/10.2174/012210299X257270231127062630
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/2/1/CIS-2-E2210299X257270.html?itemId=/content/journals/cis/10.2174/012210299X257270231127062630&mimeType=html&fmt=ahah

References

  1. InzucchiS.E. SherwinR.S. Type 2 diabetes mellitus. Cecil Medicine.24th edPhiladelphia, PaSaunders Elsevier2011
     [Google Scholar]
  2. KaoK.T. SabinM.A. Type 2 diabetes mellitus in children and adolescents.Aust. Fam. Physician201645640140627622231
     [Google Scholar]
  3. OlokobaA.B. ObateruO.A. OlokobaL.B. Type 2 diabetes mellitus: a review of current trends.Oman Med. J.201227426927310.5001/omj.2012.6823071876
     [Google Scholar]
  4. American Diabetes AssociationDiagnosis and classification of diabetes mellitus.Diabetes Care201336S1S67S7410.2337/dc13‑S06723264425
     [Google Scholar]
  5. MayfieldJ. Diagnosis and classification of diabetes mellitus: New criteria.Am. Fam. Physician199858613551362, 1369-13709803200
     [Google Scholar]
  6. ChaturvediN. The burden of diabetes and its complications: Trends and implications for intervention.Diabetes Res. Clin. Pract.2007763S3S1210.1016/j.diabres.2007.01.01917343954
     [Google Scholar]
  7. VigerskyR.A. An overview of management issues in adult patients with type 2 diabetes mellitus.J. Diabetes Sci. Technol.20115224525010.1177/19322968110050020721527089
     [Google Scholar]
  8. FongD.S. AielloL. GardnerT.W. KingG.L. BlankenshipG. CavalleranoJ.D. FerrisF.L.III KleinR. Retinopathy in diabetes.Diabetes Care200427S1s84s8710.2337/diacare.27.2007.S8414693935
     [Google Scholar]
  9. WuY. DingY. TanakaY. ZhangW. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.Int. J. Med. Sci.201411111185120010.7150/ijms.1000125249787
     [Google Scholar]
  10. KernerW. BrückelJ. Definition, classification and diagnosis of diabetes mellitus.Exp. Clin. Endocrinol. Diabetes2014122738438610.1055/s‑0034‑136627825014088
     [Google Scholar]
  11. SosaleA. Prasanna KumarK.M. SadikotS.M. NigamA. BajajS. ZargarA.H. SinghS.K. Chronic complications in newly diagnosed patients with Type 2 diabetes mellitus in India.Indian J. Endocrinol. Metab.201418335536010.4103/2230‑8210.13118424944931
     [Google Scholar]
  12. KumarP.R. BhansaliA. RavikiranM. BhansaliS. DuttaP. ThakurJ.S. SachdevaN. BhadadaS.K. WaliaR. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study.J. Clin. Endocrinol. Metab.20109562832283510.1210/jc.2009‑243320371663
     [Google Scholar]
  13. CoxM.E. EdelmanD. Tests for screening and diagnosis of type 2 diabetes.Clin. Diabetes200927413213810.2337/diaclin.27.4.132
     [Google Scholar]
  14. GenuthS. AlbertiK.G. BennettP. BuseJ. DefronzoR. KahnR. KitzmillerJ. KnowlerW.C. LebovitzH. LernmarkA. NathanD. PalmerJ. RizzaR. SaudekC. ShawJ. SteffesM. SternM. TuomilehtoJ. ZimmetP. Follow-up report on the diagnosis of diabetes mellitus.Diabetes Care200326113160316710.2337/diacare.26.11.316014578255
     [Google Scholar]
  15. PerryR.C. ShankarR.R. FinebergN. McGillJ. BaronA.D. HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: The Early Diabetes Intervention Program (EDIP).Diabetes Care200124346547110.2337/diacare.24.3.46511289469
     [Google Scholar]
  16. DedovI. ShestakovaM. BenedettiM.M. SimonD. PakhomovI. GalstyanG. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study).Diabetes Res. Clin. Pract.2016115909510.1016/j.diabres.2016.02.01027107818
     [Google Scholar]
  17. StrimbuK. TavelJ.A. What are biomarkers?Curr. Opin. HIV AIDS20105646346610.1097/COH.0b013e32833ed17720978388
     [Google Scholar]
  18. MayeuxR. Biomarkers: Potential uses and limitations.NeuroRx20041218218810.1602/neurorx.1.2.18215717018
     [Google Scholar]
  19. LaaksoM. Biomarkers for type 2 diabetes.Mol. Metab.201927S139S14610.1016/j.molmet.2019.06.01631500825
     [Google Scholar]
  20. EhtewishH ArredouaniA El-AgnafO. Diagnostic, prognostic, and mechanistic biomarkers of diabetes mellitus-associated cognitive decline.Int J Mol Sci.20222311614410.3390/ijms23116144
     [Google Scholar]
  21. SciricaB.M. Use of biomarkers in predicting the onset, monitoring the progression, and risk stratification for patients with type 2 diabetes mellitus.Clin. Chem.201763118619510.1373/clinchem.2016.25553928062618
     [Google Scholar]
  22. LuísC. BaylinaP. SoaresR. FernandesR. Metabolic dysfunction biomarkers as predictors of early diabetes.Biomolecules20211111158910.3390/biom1111158934827587
     [Google Scholar]
  23. PenaM.J. HeinzelA. HeinzeG. AlkhalafA. BakkerS.J.L. NguyenT.Q. GoldschmedingR. BiloH.J.G. PercoP. MayerB. de ZeeuwD. Lambers HeerspinkH.J. A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes.PLoS One2015105e012099510.1371/journal.pone.012099525973922
     [Google Scholar]
  24. Padilla-MartinezF. WojciechowskaG. SzczerbinskiL. KretowskiA. Circulating nucleic acid-based biomarkers of type 2 diabetes.Int. J. Mol. Sci.202123129510.3390/ijms2301029535008723
     [Google Scholar]
  25. Jiménez-LucenaR. Rangel-ZúñigaO.A. Alcalá-DíazJ.F. López-MorenoJ. Roncero-RamosI. Molina-AbrilH. Yubero-SerranoE.M. Caballero-VillarrasoJ. Delgado-ListaJ. CastañoJ.P. OrdovásJ.M. Pérez-MartinezP. CamargoA. López-MirandaJ. Circulating miRNAs as predictive biomarkers of type 2 diabetes mellitus development in coronary heart disease patients from the CORDIOPREV study.Mol. Ther. Nucleic Acids20181214615710.1016/j.omtn.2018.05.00230195754
     [Google Scholar]
  26. HiguchiC. NakatsukaA. EguchiJ. TeshigawaraS. KanzakiM. KatayamaA. YamaguchiS. TakahashiN. MurakamiK. OgawaD. SasakiS. MakinoH. WadaJ. Identification of Circulating miR-101, miR-375 and miR-802 as Biomarkers for Type 2 Diabetes.Metabolism201564448949710.1016/j.metabol.2014.12.00325726255
     [Google Scholar]
  27. Sánchez-CeinosJ. Rangel-ZuñigaO.A. Clemente-PostigoM. Podadera-HerrerosA. CamargoA. Alcalá-DiazJ.F. Guzmán-RuizR. López-MirandaJ. MalagónM.M. miR-223-3p as a potential biomarker and player for adipose tissue dysfunction preceding type 2 diabetes onset.Mol. Ther. Nucleic Acids2021231035105210.1016/j.omtn.2021.01.01433614249
     [Google Scholar]
  28. VasuS. KumanoK. DardenC.M. RahmanI. LawrenceM.C. NaziruddinB. MicroRNA signatures as future biomarkers for diagnosis of diabetes states.Cells2019812153310.3390/cells812153331795194
     [Google Scholar]
  29. GuayC. RegazziR. Circulating microRNAs as novel biomarkers for diabetes mellitus.Nat. Rev. Endocrinol.20139951352110.1038/nrendo.2013.8623629540
     [Google Scholar]
  30. ChiT. LinJ. WangM. ZhaoY. LiaoZ. WeiP. Non-coding RNA as biomarkers for Type 2 diabetes development and clinical management.Front. Endocrinol.20211263003210.3389/fendo.2021.63003234603195
     [Google Scholar]
  31. CiobanuD.M. BogdanF. PătruțC.I. RomanG. Glycated albumin is correlated with glycated hemoglobin in type 2 diabetes.Med. Pharm. Rep.201992213413810.15386/mpr‑124731086840
     [Google Scholar]
  32. YoshiuchiK. MatsuhisaM. KatakamiN. NakataniY. SakamotoK. MatsuokaT. UmayaharaY. KosugiK. KanetoH. YamasakiY. HoriM. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes.Endocr. J.200855350350710.1507/endocrj.K07E‑08918445997
     [Google Scholar]
  33. RescalliA. VaroniE.M. CellesiF. CerveriP. Analytical challenges in diabetes management: Towards glycated albumin point-of-care detection.Biosensors202212968710.3390/bios1209068736140073
     [Google Scholar]
  34. ToftJ.H. DalenI. SkadbergØ. GøranssonL.G. ØklandI. BleskestadI.H. Glycated albumin and continuous glucose monitoring metrics across pregnancy in women with pre‐gestational diabetes.Endocrinol. Diabetes Metab.202256e37610.1002/edm2.37636121204
     [Google Scholar]
  35. SierawskaO. Niedźwiedzka-RystwejP. Adipokines as potential biomarkers for type 2 diabetes mellitus in cats.Front. Immunol.20221395004910.3389/fimmu.2022.95004936248900
     [Google Scholar]
  36. BowkerN. ShahR.L. SharpS.J. LuanJ. StewartI.D. WheelerE. FerreiraM.A.R. BarasA. WarehamN.J. LangenbergC. LottaL.A. Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes.EBioMedicine20206110306210.1016/j.ebiom.2020.10306233096487
     [Google Scholar]
  37. MalmströmH. WalldiusG. GrillV. JungnerI. GudbjörnsdottirS. HammarN. Fructosamine is a useful indicator of hyperglycaemia and glucose control in clinical and epidemiological studies--cross-sectional and longitudinal experience from the AMORIS cohort.PLoS One2014910e11146310.1371/journal.pone.011146325353659
     [Google Scholar]
  38. BergmanM. Abdul-GhaniM. DeFronzoR.A. MancoM. SestiG. FiorentinoT.V. CerielloA. RheeM. PhillipsL.S. ChungS. CravalhoC. JagannathanR. MonnierL. ColetteC. OwensD. BianchiC. del PratoS. MonteiroM.P. NevesJ.S. MedinaJ.L. MacedoM.P. RibeiroR.T. Filipe RaposoJ. DorcelyB. IbrahimN. BuysschaertM. Review of methods for detecting glycemic disorders.Diabetes Res. Clin. Pract.202016510823310.1016/j.diabres.2020.10823332497744
     [Google Scholar]
  39. AmitaD. DhirajK. VivekS. SatyaP.M. The novel biomarkers in diabetes.J Assoc Physicians India20196776569
     [Google Scholar]
  40. PramodkumarT.A. JayashriR. GokulakrishnanK. VelmuruganK. PradeepaR. VenkatesanU. SaravananP. UmaR. AnjanaR.M. MohanV. 1,5 Anhydroglucitol in gestational diabetes mellitus.J. Diabetes Complications201933323123510.1016/j.jdiacomp.2018.11.01030594413
     [Google Scholar]
  41. Ortiz-MartínezM. González-GonzálezM. MartagónA.J. HlavinkaV. WillsonR.C. Rito-PalomaresM. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus.Curr. Diab. Rep.20222239511510.1007/s11892‑022‑01453‑435267140
     [Google Scholar]
  42. ChonS. LeeY.J. FraterrigoG. PozzilliP. ChoiM.C. KwonM.K. ChinS.O. RheeS.Y. OhS. KimY.S. WooJ.T. Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.Diabetes Technol. Ther.201315645546010.1089/dia.2012.031523617251
     [Google Scholar]
  43. ChanC.L. PyleL. KelseyM. NewnesL. ZeitlerP.S. NadeauK.J. Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia - 1,5-anhydroglucitol, fructosamine, and glycated albumin.Pediatr. Diabetes201617320621110.1111/pedi.1225825652226
     [Google Scholar]
  44. UedaS. NagaiK. YokotaN. HiroseD. MoriH. NomaY. DoiT. MinakuchiJ. Influence of albumin leakage on glycated albumin in patients with type 2 diabetes undergoing hemodialysis.J. Artif. Organs201922326426710.1007/s10047‑019‑01097‑430805746
     [Google Scholar]
  45. LiuL. WanX. LiuJ. HuangZ. CaoX. LiY. Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy.Diabetes Technol. Ther.201214975676110.1089/dia.2012.005522731793
     [Google Scholar]
  46. DorcelyB. KatzK. JagannathanR. ChiangS.S. OluwadareB. GoldbergI.J. BergmanM. Novel biomarkers for prediabetes, diabetes, and associated complications.Diabetes Metab. Syndr. Obes.20171034536110.2147/DMSO.S10007428860833
     [Google Scholar]
  47. Aghaei ZarchS.M. Dehghan TezerjaniM. TalebiM. Vahidi MehrjardiM.Y. Molecular biomarkers in diabetes mellitus (DM).Med. J. Islam. Repub. Iran2020342810.34171/mjiri.34.2832617267
     [Google Scholar]
  48. HilvoM. VasileV.C. DonatoL.J. HurmeR. LaaksonenR. Ceramides and ceramide scores: Clinical applications for cardiometabolic risk stratification.Front. Endocrinol.20201157062810.3389/fendo.2020.57062833133018
     [Google Scholar]
  49. GallW.E. BeebeK. LawtonK.A. AdamK.P. MitchellM.W. NakhleP.J. RyalsJ.A. MilburnM.V. NannipieriM. CamastraS. NataliA. FerranniniE. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population.PLoS One201055e1088310.1371/journal.pone.001088320526369
     [Google Scholar]
  50. LandaasS. The formation of 2-hydroxybutyric acid in experimental animals.Clin. Chim. Acta1975581233210.1016/0009‑8981(75)90481‑7
     [Google Scholar]
  51. GarC. RottenkolberM. PrehnC. AdamskiJ. SeisslerJ. LechnerA. Serum and plasma amino acids as markers of prediabetes, insulin resistance, and incident diabetes.Crit. Rev. Clin. Lab. Sci.2018551213210.1080/10408363.2017.141414329239245
     [Google Scholar]
  52. SaltevoJ. KautiainenH. VanhalaM. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes.Gend. Med.20096346347010.1016/j.genm.2009.09.00619850242
     [Google Scholar]
  53. ZhangX. ZhangC. ChenL. HanX. JiL. Human serum acylcarnitine profiles in different glucose tolerance states.Diabetes Res. Clin. Pract.2014104337638210.1016/j.diabres.2014.04.01324837145
     [Google Scholar]
  54. SunL. LiangL. GaoX. ZhangH. YaoP. HuY. MaY. WangF. JinQ. LiH. LiR. LiuY. HuF.B. ZengR. LinX. WuJ. Early prediction of developing type 2 diabetes by plasma acylcarnitines: A population-based study.Diabetes Care20163991563157010.2337/dc16‑023227388475
     [Google Scholar]
  55. Ruiz-CanelaM. Guasch-FerréM. ToledoE. ClishC.B. RazquinC. LiangL. WangD.D. CorellaD. EstruchR. HernáezÁ. YuE. Gómez-GraciaE. ZhengY. ArósF. RomagueraD. DennisC. RosE. LapetraJ. Serra-MajemL. PapandreouC. PortolesO. FitóM. Salas-SalvadóJ. HuF.B. Martínez-GonzálezM.A. Plasma branched chain/aromatic amino acids, enriched Mediterranean diet and risk of type 2 diabetes: case-cohort study within the PREDIMED Trial.Diabetologia20186171560157110.1007/s00125‑018‑4611‑529663011
     [Google Scholar]
  56. ChenX. YangW. Branched‐chain amino acids and the association with type 2 diabetes.J. Diabetes Investig.20156436937010.1111/jdi.1234526221513
     [Google Scholar]
  57. SabanayagamC. ShankarA. LimS.C. LeeJ. TaiE.S. WongT.Y. Serum C-reactive protein level and prediabetes in two Asian populations.Diabetologia201154476777510.1007/s00125‑011‑2052‑521267537
     [Google Scholar]
  58. GrossmannV. SchmittV.H. ZellerT. Panova-NoevaM. SchulzA. Laubert-RehD. JuengerC. SchnabelR.B. AbtT.G.J. LaskowskiR. WiltinkJ. SchulzE. BlankenbergS. LacknerK.J. MünzelT. WildP.S. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes.Diabetes Care20153871356136410.2337/dc14‑300825877811
     [Google Scholar]
  59. KunutsorS.K. ApekeyT.A. WalleyJ. KainK. Ferritin levels and risk of type 2 diabetes mellitus: An updated systematic review and meta-analysis of prospective evidence.Diabetes Metab. Res. Rev.201329430831810.1002/dmrr.239423381919
     [Google Scholar]
  60. ForouhiN.G. HardingA.H. AllisonM. SandhuM.S. WelchA. LubenR. BinghamS. KhawK.T. WarehamN.J. Elevated serum ferritin levels predict new-onset type 2 diabetes: Results from the EPIC-Norfolk prospective study.Diabetologia200750594995610.1007/s00125‑007‑0604‑517333112
     [Google Scholar]
  61. LeeJ.E. Alternative biomarkers for assessing glycemic control in diabetes: Fructosamine, glycated albumin, and 1,5-anhydroglucitol.Ann. Pediatr. Endocrinol. Metab.2015202747810.6065/apem.2015.20.2.7426191510
     [Google Scholar]
  62. DaneseE. MontagnanaM. NouvenneA. LippiG. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes.J. Diabetes Sci. Technol.20159216917610.1177/193229681456722725591856
     [Google Scholar]
  63. LongJ. YangZ. WangL. HanY. PengC. YanC. YanD. Metabolite biomarkers of type 2 diabetes mellitus and pre-diabetes: A systematic review and meta-analysis.BMC Endocr. Disord.202020117410.1186/s12902‑020‑00653‑x33228610
     [Google Scholar]
  64. Wang-SattlerR. YuZ. HerderC. MessiasA.C. FloegelA. HeY. HeimK. CampillosM. HolzapfelC. ThorandB. GrallertH. XuT. BaderE. HuthC. MittelstrassK. DöringA. MeisingerC. GiegerC. PrehnC. Roemisch-MarglW. CarstensenM. XieL. Yamanaka-OkumuraH. XingG. CeglarekU. ThieryJ. GianiG. LickertH. LinX. LiY. BoeingH. JoostH.G. de AngelisM.H. RathmannW. SuhreK. ProkischH. PetersA. MeitingerT. RodenM. WichmannH.E. PischonT. AdamskiJ. IlligT. Novel biomarkers for pre‐diabetes identified by metabolomics.Mol. Syst. Biol.20128161510.1038/msb.2012.4323010998
     [Google Scholar]
  65. Pérez-MatosM.C. Morales-ÁlvarezM.C. TolozaF.J.K. Ricardo-SilgadoM.L. Mantilla-RivasJ.O. Pinzón-CortesJ.A. Perez-MayorgaM. JiménezE. GuevaraE. MendivilC.O. The phospholipid linoleoylglycerophosphocholine as a biomarker of directly measured insulin resistance.Diabetes Metab. J.201741646647310.4093/dmj.2017.41.6.46629199411
     [Google Scholar]
  66. AhnN. BaumeisterS.E. AmannU. RathmannW. PetersA. HuthC. ThorandB. MeisingerC. Visceral adiposity index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes.Sci. Rep.201991969310.1038/s41598‑019‑46187‑831273286
     [Google Scholar]
  67. HamasakiH. NodaM. MoriyamaS. YoshikawaR. KatsuyamaH. SakoA. MishimaS. KakeiM. EzakiO. YanaiH. Daily physical activity assessed by a triaxial accelerometer is beneficially associated with waist circumference, serum triglycerides, and insulin resistance in japanese patients with prediabetes or untreated early type 2 diabetes.J. Diabetes Res.201520151610.1155/2015/52620126064983
     [Google Scholar]
  68. BarrR.G. NathanD.M. MeigsJ.B. SingerD.E. Tests of glycemia for the diagnosis of type 2 diabetes mellitus.Ann. Intern. Med.2002137426327210.7326/0003‑4819‑137‑4‑200208200‑0001112186517
     [Google Scholar]
  69. JiangY. OweiI. WanJ. EbeniboS. Dagogo-JackS. Adiponectin levels predict prediabetes risk: The pathobiology of prediabetes in a biracial cohort (POP-ABC) study.BMJ Open Diabetes Res. Care201641e00019410.1136/bmjdrc‑2016‑00019427026810
     [Google Scholar]
  70. PescadorN. Pérez-BarbaM. IbarraJ.M. CorbatónA. Martínez-LarradM.T. Serrano-RíosM. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers.PLoS One2013810e7725110.1371/journal.pone.007725124204780
     [Google Scholar]
  71. BelgardtB.F. AhmedK. SprangerM. LatreilleM. DenzlerR. KondratiukN. von MeyennF. VillenaF.N. HerrmannsK. BoscoD. Kerr-ConteJ. PattouF. RülickeT. StoffelM. The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes.Nat. Med.201521661962710.1038/nm.386225985365
     [Google Scholar]
  72. HeA. ZhuL. GuptaN. ChangY. FangF. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes.Mol. Endocrinol.200721112785279410.1210/me.2007‑016717652184
     [Google Scholar]
  73. StefanN. SunQ. FritscheA. MachannJ. SchickF. GerstF. JeppesenC. JoostH.G. HuF.B. BoeingH. UllrichS. HäringH.U. SchulzeM.B. Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: Prospective cohort- and cross-sectional phenotyping studies.PLoS One201493e9223810.1371/journal.pone.009223824643166
     [Google Scholar]
/content/journals/cis/10.2174/012210299X257270231127062630
Loading
Mechanistic Insight of Innovative Biomarkers for Screening of Type II Diabetes Mellitus
Curr. Indian Sci. 2, E2210299X257270 (2024); https://doi.org/10.2174/012210299X257270231127062630
/content/journals/cis/10.2174/012210299X257270231127062630
/content/journals/cis/10.2174/012210299X257270231127062630
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Conventional biomarker; Diabetes mellitus; Diagnosis; Hb1Ac; Insulin; Screening technique

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test